AVDL (avadel.com) Rasio nilai perusahaan marang pendapatan

Logo perusahaan publik Avadel Pharmaceuticals plc (AVDL)

Avadel Pharmaceuticals generates revenue through the exclusive distribution of LUMRYZ for the treatment of narcolepsy. High customer retention is driven by a unique dosing regimen approved by the FDA. The EV-to-revenue ratio on the GURU.Markets chart demonstrates the fundamental value of the assets, where 8299.61 characterizes this valuation parameter. High profitability with a minimal workforce is achieved through a proprietary slow-release formula.

AVDL Multiplikator EV/Sales avadel.com (23.11.2025 - 28.02.2026)

AVDL (Avadel Pharma): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator valuasi pasar bisnis:
Pambiji fundamental:avadel.com AVDL
Barang utama Avadel Pharmaceuticals PLC

Efficient logistics for sleep medications at Avadel Pharmaceuticals (AVDL) directly impact the EV/Sales ratio dynamics. This metric compares the total enterprise value of the business to annual revenue, excluding the influence of debt load. The calculation combines market capitalization and net debt, divided by revenue. Aggressive growth in this indicator may mask fundamental risks of asset overvaluation. Investors should be wary of false optimism when the chart shows sharp deviations from industry averages.